Search

Your search keyword '"Oguchi, Tomohiko"' showing total 178 results
Start Over Author "Oguchi, Tomohiko"
178 results on '"Oguchi, Tomohiko"'

2. A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

Author

Yoshida, Soichiro, Takahara, Taro, Arita, Yuki, Ito, Masaya, Hayakawa, Sara, Oguchi, Tomohiko, Komai, Yoshinobu, Numao, Noboru, Yuasa, Takeshi, Inoue, Masaharu, Ushijima, Hiroki, Kudo, Shigehiro, Shimano, Yasumasa, Nakamura, Yuki, Uchida, Yusuke, Uehara, Sho, Tanaka, Hajime, Yaegashi, Hiroshi, Izumi, Kouji, Yokoyama, Minato, Matsuoka, Yoh, Yoshioka, Yasuo, Konishi, Koji, Nakanishi, Katsuyuki, Nagahara, Akira, Hirakawa, Akihiro, Koike, Ryuji, Koga, Fumitaka, Nishimura, Kazuo, Mizokami, Atsushi, Yonese, Junji, Kageyama, Yukio, Yoshimura, Ryoichi, and Fujii, Yasuhisa

Published
2023
Full Text
View/download PDF

9. Clinical Outcomes and Prognostic Factors in Nonmetastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Signaling Inhibitors Therapy.

Author

Fujiwara, Ryo, Yamamoto, Shinya, Takemura, Kosuke, Yuasa, Takeshi, Numao, Noboru, Oguchi, Tomohiko, Yasuda, Yosuke, Yoneoka, Yusuke, and Yonese, Junji

Subjects
CASTRATION-resistant prostate cancer, ABIRATERONE acetate, PROSTATE-specific antigen, HUMAN beings, TREATMENT effectiveness, RETROSPECTIVE studies, DESCRIPTIVE statistics, MULTIVARIATE analysis, KAPLAN-Meier estimator, MEDICAL records, ACQUISITION of data, PROGRESSION-free survival, ANDROGEN receptors, PROPORTIONAL hazards models
Abstract

Simple Summary: We retrospectively evaluated the clinical outcomes and prognostic factors of 127 patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with first-line androgen receptor signaling inhibitors (ARSI) in real-world clinical practice. Overall survival (OS), metastatic-free survival (MFS), and prostate-specific antigen–progression-free survival (PSA–PFS) from the initiation of ARSI were assessed. The median OS and MFS for all patients were 79.0 and 42.0 months, respectively. Median PSA–PFS varied among patients treated with enzalutamide, abiraterone acetate, apalutamide, and darolutamide (27.0, 20.0, 10.0, and 14.0 months, respectively; p = 0.33). Multivariate analysis indicated that a baseline PSA level of ≥3.67 ng/mL (p = 0.002) was significantly associated with poorer OS prognosis. ARSI demonstrated favorable efficacy in nmCRPC patients, with no significant differences in clinical outcomes among different types of ARSI. High baseline PSA of ARSI was found to have a significantly poor prognosis associated with OS. We conducted a retrospective evaluation of the clinical outcomes and prognostic factors in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with first-line androgen receptor signaling inhibitors (ARSI) in real-world clinical practice in Japan. Between 2012 and 2023, a total of 127 consecutive patients with nmCRPC received ARSI treatment. Overall survival (OS), metastatic-free survival (MFS), and prostate-specific antigen–progression-free survival (PSA–PFS) from ARSI initiation were assessed using the Kaplan–Meier methodology. Clinical factors associated with OS in nmCRPC were analyzed using the Cox proportional hazards model. Among the patients, 72, 26, 12, and 17 received enzalutamide (ENZ), abiraterone (ABI), apalutamide (APA), and darolutamide (DARO) as first-line therapy. The median OS and MFS for all patients were 79.0 and 42.0 months, respectively. Median PSA–PFS was 27.0, 20.0, 10.0, and 14.0 months for patients treated with ENZ, ABI, APA, and DARO, respectively (p = 0.33). Multivariate analysis revealed that a baseline PSA level ≥ 3.67 ng/mL at ARSI initiation was significantly associated with poorer OS (p = 0.002). ARSI demonstrated favorable efficacy in nmCRPC patients. There were no significant differences in clinical outcomes among different types of ARSI therapy for nmCRP. Elevated baseline PSA at ARSI initiation was significantly associated with poorer OS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Prognostic Significance of Immune-related Adverse Events in Metastatic Renal Cell Carcinoma Patients Treated With Immune-checkpoint-inhibitors

Author

YASUDA, YOSUKE, primary, FUJIWARA, RYO, additional, OGUCHI, TOMOHIKO, additional, KOMAI, YOSHINOBU, additional, NUMAO, NOBORU, additional, YAMAMOTO, SHINYA, additional, OKI, RYOSUKE, additional, URASAKI, TETSUYA, additional, TAKAHASHI, SHUNJI, additional, YONESE, JUNJI, additional, and YUASA, TAKESHI, additional

Published
2023
Full Text
View/download PDF

13. Additional file 3 of A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

Author

Yoshida, Soichiro, Takahara, Taro, Arita, Yuki, Ito, Masaya, Hayakawa, Sara, Oguchi, Tomohiko, Komai, Yoshinobu, Numao, Noboru, Yuasa, Takeshi, Inoue, Masaharu, Ushijima, Hiroki, Kudo, Shigehiro, Shimano, Yasumasa, Nakamura, Yuki, Uchida, Yusuke, Uehara, Sho, Tanaka, Hajime, Yaegashi, Hiroshi, Izumi, Kouji, Yokoyama, Minato, Matsuoka, Yoh, Yoshioka, Yasuo, Konishi, Koji, Nakanishi, Katsuyuki, Nagahara, Akira, Hirakawa, Akihiro, Koike, Ryuji, Koga, Fumitaka, Nishimura, Kazuo, Mizokami, Atsushi, Yonese, Junji, Kageyama, Yukio, Yoshimura, Ryoichi, and Fujii, Yasuhisa

Abstract

Additional file 3: The consent form given to participants.

Published
2023
Full Text
View/download PDF

14. Additional file 2 of A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

Author

Yoshida, Soichiro, Takahara, Taro, Arita, Yuki, Ito, Masaya, Hayakawa, Sara, Oguchi, Tomohiko, Komai, Yoshinobu, Numao, Noboru, Yuasa, Takeshi, Inoue, Masaharu, Ushijima, Hiroki, Kudo, Shigehiro, Shimano, Yasumasa, Nakamura, Yuki, Uchida, Yusuke, Uehara, Sho, Tanaka, Hajime, Yaegashi, Hiroshi, Izumi, Kouji, Yokoyama, Minato, Matsuoka, Yoh, Yoshioka, Yasuo, Konishi, Koji, Nakanishi, Katsuyuki, Nagahara, Akira, Hirakawa, Akihiro, Koike, Ryuji, Koga, Fumitaka, Nishimura, Kazuo, Mizokami, Atsushi, Yonese, Junji, Kageyama, Yukio, Yoshimura, Ryoichi, and Fujii, Yasuhisa

Abstract

Additional file 2: The explanatory document translated to English (the original document is written in Japanese).

Published
2023
Full Text
View/download PDF

15. Additional file 1 of A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

Author

Yoshida, Soichiro, Takahara, Taro, Arita, Yuki, Ito, Masaya, Hayakawa, Sara, Oguchi, Tomohiko, Komai, Yoshinobu, Numao, Noboru, Yuasa, Takeshi, Inoue, Masaharu, Ushijima, Hiroki, Kudo, Shigehiro, Shimano, Yasumasa, Nakamura, Yuki, Uchida, Yusuke, Uehara, Sho, Tanaka, Hajime, Yaegashi, Hiroshi, Izumi, Kouji, Yokoyama, Minato, Matsuoka, Yoh, Yoshioka, Yasuo, Konishi, Koji, Nakanishi, Katsuyuki, Nagahara, Akira, Hirakawa, Akihiro, Koike, Ryuji, Koga, Fumitaka, Nishimura, Kazuo, Mizokami, Atsushi, Yonese, Junji, Kageyama, Yukio, Yoshimura, Ryoichi, and Fujii, Yasuhisa

Abstract

Additional file 1: SPIRIT 2013 Checklist for the MEDAL trial.

Published
2023
Full Text
View/download PDF

16. Renal function outcome after selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and consolidative partial cystectomy in comparison with radical cystectomy for patients with muscle-invasive bladder cancer: a two-centre retrospective study

Author

Fujiwara, Motohiro, primary, Yokoyama, Minato, additional, Toide, Masahiro, additional, Fujiwara, Ryo, additional, Tanaka, Hajime, additional, Oguchi, Tomohiko, additional, Komai, Yoshinobu, additional, Yoshida, Soichiro, additional, Matsuoka, Yoh, additional, Numao, Noboru, additional, Yamamoto, Shinya, additional, Fukui, Iwao, additional, Yonese, Junji, additional, and Fujii, Yasuhisa, additional

Published
2022
Full Text
View/download PDF

21. PD22-05 COMPARISON OF LOW-DOSE-RATE BRACHYTHERAPY VERSUS RADICAL PROSTATECTOMY IN PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER: A PROPENSITY-MATCHED MULTI-INSTITUTIONAL STUDY

Author

Tsumura, Hideyasu, primary, Tanaka, Nobumichi, additional, Oguchi, Tomohiko, additional, Owari, Takuya, additional, Nakai, Yasushi, additional, Asakawa, Isao, additional, Iijima, Kazuyoshi, additional, Kato, Haruaki, additional, Hashida, Iwao, additional, Tabata, Ken-ichi, additional, Satoh, Takefumi, additional, and Ishiyama, Hiromichi, additional

Published
2022
Full Text
View/download PDF

23. Additional file 1 of Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer

Author

Tsumura, Hideyasu, Tanaka, Nobumichi, Oguchi, Tomohiko, Owari, Takuya, Nakai, Yasushi, Asakawa, Isao, Iijima, Kazuyoshi, Kato, Haruaki, Hashida, Iwao, Tabata, Ken-ichi, Satoh, Takefumi, and Ishiyama, Hiromichi

Subjects
food and beverages
Abstract

Additional file 1. Table S1. Causes of death in patients treated with SEED-BT and RP.

Published
2022
Full Text
View/download PDF

27. Comparative Effectiveness Of Low-Dose-Rate Brachytherapy Alone Or Combined With External-Beam Radiotherapy In Intermediate-Risk Prostate Cancer: A Propensity-Matched Multi-Institutional Study

Author

Tsumura, Hideyasu, primary, Tanaka, Nobumichi, additional, Oguchi, Tomohiko, additional, Owari, Takuya, additional, Nakai, Yasushi, additional, Asakawa, Isao, additional, Iijima, Kazuyoshi, additional, Kato, Haruaki, additional, Hashida, Iwao, additional, Tabata, Ken-ichi, additional, Satoh, Takefumi, additional, and Ishiyama, Hiromichi, additional

Published
2022
Full Text
View/download PDF

28. Direct Comparison of Low-Dose-Rate Brachytherapy Versus Radical Prostatectomy Using the Surgical Definition of Biochemical Recurrence for Patients with Intermediate-Risk Prostate Cancer

Author

Tsumura, Hideyasu, primary, Tanaka, Nobumichi, additional, Oguchi, Tomohiko, additional, Owari, Takuya, additional, Nakai, Yasushi, additional, Asakawa, Isao, additional, Iijima, Kazuyoshi, additional, Kato, Haruaki, additional, Hashida, Iwao, additional, Tabata, Ken-ichi, additional, Satoh, Takefumi, additional, and Ishiyama, Hiromichi, additional

Published
2022
Full Text
View/download PDF

30. Renal function outcome after selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and consolidative partial cystectomy in comparison with radical cystectomy for patients with muscle-invasive bladder cancer: a two-centre retrospective study

Author

Fujiwara, Motohiro, Yokoyama, Minato, Toide, Masahiro, Fujiwara, Ryo, Tanaka, Hajime, Oguchi, Tomohiko, Komai, Yoshinobu, Yoshida, Soichiro, Matsuoka, Yoh, Numao, Noboru, Yamamoto, Shinya, Fukui, Iwao, Yonese, Junji, and Fujii, Yasuhisa

Published
2023
Full Text
View/download PDF

31. Geriatric Nutritional Risk Index as a Predictor of Prognosis in Metastatic Renal Cell Carcinoma Treated with Nivolumab.

Author

Fujiwara, Ryo, Yuasa, Takeshi, Yamamoto, Shinya, Fujiwara, Motohiro, Takemura, Kosuke, Urasaki, Tetsuya, Oki, Ryosuke, Komai, Yoshinobu, Oguchi, Tomohiko, Numao, Noboru, and Yonese, Junji

Subjects
RENAL cell carcinoma, NUTRITIONAL assessment, RESEARCH methodology evaluation, RESEARCH methodology, METASTASIS, RETROSPECTIVE studies, GERIATRIC nutrition, NIVOLUMAB, RESEARCH funding, DESCRIPTIVE statistics, KARNOFSKY Performance Status, PREDICTIVE validity, OVERALL survival, EVALUATION
Abstract

The Geriatric Nutritional Risk Index (GNRI) has been reported as a screening tool to assess the nutrition-related risk with mortality in older patients and those with the various diseases. However, the prognostic value of GNRI in metastatic renal cell carcinoma (mRCC) patients receiving nivolumab therapy remains unclear. Fifty-six consecutive patients with mRCC receiving nivolumab between September 2013 and August 2020 at our institution were retrospectively analyzed. The survival outcomes and prognostic factors associated with overall survival (OS) were statistically analyzed. Thirteen and forty-three patients were classified with low (GNRI < 92) and high (GNRI ≥ 92) GNRI, respectively. Patients with low GNRI demonstrated significantly shorter OS (P = 0.0002) than those with high GNRI. In multivariate analysis, GNRI at the time of nivolumab (P = 0.008) was extracted as the predictor for OS in addition to Karnofsky performance status (KPS) (P = 0.016). Integration of the GNRI into the International Metastatic Renal Cell Cancer Database Consortium (IMDC) risk classification improved the c-index from 0.761 to 0.833 (combination of GNRI with IMDC risk classification) and to 0.778 (substitution of GNRI with KPS in IMDC risk classification). GNRI was a significant prognostic biomarker in mRCC patients receiving nivolumab. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. MP15-17 PREDICTION MODEL FOR SIDE-SPECIFIC LYMPH NODE INVASION IN RADICAL PROSTATECTOMY AMONG PATIENTS WITH PROSTATE CANCER: FEASIBILITY OF SIDE-SPECIFIC LYMPH NODE DISSECTION

Author

Fukagawa, Eri, primary, Numao, Noboru, additional, Yamamoto, Shinya, additional, Yoshitomi, Kasumi, additional, Hamada, Kosuke, additional, Yoneoka, Yusuke, additional, Fujiwara, Motohiro, additional, Fujiwara, Ryo, additional, Komai, Yoshinobu, additional, Oguchi, Tomohiko, additional, Yuasa, Takeshi, additional, Fukui, Iwao, additional, and Yonese, Junji, additional

Published
2021
Full Text
View/download PDF

34. The utility of diffusion‐weighted whole‐body imaging with background body signal suppression in detecting metastatic lesion of germ cell carcinoma

Author

Yoshitomi, Kasumi Kaneko, primary, Numao, Noboru, additional, Umino, Yosuke, additional, Fujiwara, Motohiro, additional, Fujiwara, Ryo, additional, Oguchi, Tomohiko, additional, Komai, Yoshinobu, additional, Yuasa, Takeshi, additional, Yamamoto, Shinya, additional, and Yonese, Junji, additional

Published
2021
Full Text
View/download PDF

35. First‐line combination chemotherapy with etoposide, ifosfamide and cisplatin for the treatment of disseminated germ cell cancer: Efficacy and feasibility in current clinical practice

Author

Fujiwara, Motohiro, primary, Tanaka, Hajime, additional, Yuasa, Takeshi, additional, Komai, Yoshinobu, additional, Oguchi, Tomohiko, additional, Fujiwara, Ryo, additional, Numao, Noboru, additional, Yamamoto, Shinya, additional, Fujii, Yasuhisa, additional, Fukui, Iwao, additional, and Yonese, Junji, additional

Published
2021
Full Text
View/download PDF

37. “Crush Carving Technique” Using a Soft Coagulation Device: A Simple Method for Successful Laparoscopic Partial Nephrectomy Without Hilar Clamping

Author

Komai, Yoshinobu, primary, Hamada, Kosuke, additional, Fujiwara, Motohiro, additional, Kaneko Yoshitomi, Kasumi, additional, Ishikawa, Yudai, additional, Fukagawa, Eri, additional, Fujiwara, Ryo, additional, Oguchi, Tomohiko, additional, Numao, Noboru, additional, Yuasa, Takeshi, additional, Yamamoto, Shinya, additional, and Yonese, Junji, additional

Published
2021
Full Text
View/download PDF

42. Impact of low‐dose tadalafil on adverse events after low‐dose‐rate brachytherapy for prostate cancer: A bi‐center randomized open‐label trial

Author

Minagawa, Tomonori, primary, Oguchi, Tomohiko, additional, Saitou, Tetsuichi, additional, Fukazawa, Ayumu, additional, Hashida, Iwao, additional, Koiwai, Keiichiro, additional, Iijima, Kazuyoshi, additional, Kato, Haruaki, additional, Ogawa, Teruyuki, additional, and Ishizuka, Osamu, additional

Published
2021
Full Text
View/download PDF

43. Characteristics and Oncological Outcome of Clinical T3a Prostate Cancer Patients Undergoing Radical Prostatectomy in the Multi-Parametric MRI Era

Author

Yoshitomi, Kasumi, primary, Yamamoto, Shinya, additional, Yamamoto, Tatsuya, additional, Fukagawa, Eri, additional, Hamada, Kosuke, additional, Yoneoka, Yusuke, additional, Fujiwara, Motohiro, additional, Fujiwara, Ryo, additional, Oguchi, Tomohiko, additional, Komai, Yoshinobu, additional, Numao, Noboru, additional, Yuasa, Takeshi, additional, Fukui, Iwao, additional, and Yonese, Junji, additional

Published
2020
Full Text
View/download PDF

48. IgG4-Related Idiopathic Retroperitoneal Fibrosis : A Case Report

Author

Oguchi, Tomohiko, Okada, Masato, Endo, Fumiyasu, Hattori, Kazunori, Fujisaki, Akiko, Ikeda, Masaomi, Shiga, Yoshiyuki, Yashi, Masahiro, and Muraishi, Osamu

Subjects
IgG4, 494.9, Retroperitoneal fibrosis
Abstract

A 75-year-old man visited our hospital with the complaint of lumbago due to bilateral hydronephrosis. Computed tomographic (CT) scan revealed a thick and homogeneous retroperitoneal soft-tissue mass with isodensity to the muscle, which extended from around the kidneys to the bladder. His serum IgG4 level was extremely high. He also had proptosis. He was diagnosed as having retroperitoneal fibrosis due to IgG4- related sclerosing disease, and treated with glucocorticoid and azathioprine. After 2 months, partial regression of the mass was observed.

Published
2009

49. Cystoscopy-assisted partial cystectomy for paraganglioma of the urinary bladder

Author

Ikeda, Masaomi, Endo, Fumiyasu, Shiga, Yoshiyuki, Oguchi, Tomohiko, Yashi, Masahiro, Hattori, Kazunori, and Muraishi, Osamu

Subjects
Paraganglioma, Partial cystectomy, Cystoscopy, 494.9
Abstract

39歳女。患者は肉眼的血尿を主訴とした。膀胱鏡では膀胱後壁に3cm大の表面平滑な隆起性病変が認められ, 膀胱腫瘍の診断で経尿道的膀胱腫瘍切除術が施行された。しかし, 切除開始直後に収縮期血圧の上昇と不経脈が出現したため組織生検のみが行なわれた。以後, 再問診で約1年前から夜間排尿後の動悸や頭痛があったことが判明し, 病理組織診断はparagangliomaで, 内分泌検査では血中尿中ともにノルアドレナリンが高値であった。これらのことより, 本症例は膀胱原発褐色細胞腫と診断され, α遮断剤を投与後, 膀胱部分切除が施行された。その際, 著者らは硬性膀胱鏡による腫瘍辺縁マーキングと, 軟性膀胱鏡で切除線を透光する手技を併用する新たな膀胱部分切除術を考案し, これを施行した。本方法は簡便で確実な腫瘍切除線が決定でき, 腫瘍切除操作が血行遮断の後であるため, 安定して術中血圧管理が得られて有効であった。患者は術後, ノルアドレナリンが全て正常化し, 排尿後の動悸, 頭痛も消失した。術後8ヵ月経過で症状ならびに画像とも再発を認められていない。, A 39-year-old woman visited our hospital with a complaint of gross hematuria. Cystoscopy revealed a nodular tumor 3 cm in diameter in the posterior wall of the bladder. A transurethral resection was performed. This initial operation was complicated by unexpected intra-operative high blood pressure and visualization was obscured by bleeding. The histological diagnosis was paraganglioma. Therefore, a partial cystectomy was planned. Using cystoscopy, a 10 mm margin was identified and marked using electrocoagulation, followed by an open surgical procedure. After laparotomy, drainage veins were identified and ligated under the guidance of flexible cystoscopy lighting. Intra-operative blood pressure was stable during the operation, and the margin was negative for tumor.

Published
2008

50. Adult Wilms' tumor mimicking adrenal tumor: a case report

Author

Koizumi, Koji, Mizusawa, Hiroya, Oguchi, Tomohiko, Domen, Takahisa, and Kato, Haruaki

Subjects
Chemotherapy, Side effect, 494.9, Nephroblastoma, Retroperitoneal tumor
Abstract

33歳女。患者は右後腹膜腫瘤の精査加療を主訴とした。血管造影検査では右腎頭側の腫瘍への血管は中副腎動脈と下副腎動脈をfeederとしており, 副腎由来の腫瘍が疑われた。腎実質との交通はほとんど認めず, Hypovascularな腫瘍で, 造影剤の腫瘤部へのpoolingも軽度であった。非機能性副腎腫瘍と考え, 悪性病変も否定できないため手術を施行し, 右腎と一塊に摘出した。その結果, 病理組織学的所見では腎頭側部の腫瘍を主体としてhyperchromaticな核を有し, N/C比の高い充実性増殖が認められ, 一部はロゼット様, あるいは腺管構造を示していた。更に紡錘形の間葉系細胞様の分化や, 核の偏在傾向を示すrhabdoid tumorも含まれていた。また, 線維化, 硝子化, 石灰化, 骨化等, 多彩な病変を伴っていた。以上より, 本症例は成人腎芽腫と診断され, National Wilms' Tumor Study分類病期II・Unfavorable Histology群に相当したため, 再入院の上, 化学療法を施行したが副作用が強く中止となった。目下, 術後17ヵ月が経過しているが, 再発は認められていない。, A 33-year-old woman was referred to our hospital for further examination of a right adrenal mass 4.5 cm in diameter. Hormonal findings were normal. Computed tomography, magnetic resonance image and angiograpy demonstrated non-functioning adrenal tumor. Right nephrectomy was performed, because the tumor adhered firmly to the upper pole of the right kidney. The pathological diagnosis was nephroblastoma (nephroblastic type, complex subtype). Postoperative chemotherapy was started for stage III Wilms' tumor. However, peripheral neuropathy such as numbness of the fingers developed. Therefore, chemotherapy was discontinued in the fifth week. The patient is currently alive without recurrence 17 months postoperatively. In adult patients, postoperative chemotherapy for nephroblastoma is often interrupted due to side effects. Further studies on the protocol for adults is necessary.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results